Articles tagged with: Stem Cell Transplant
As The Beacon continues its ‘ASH Preview’ series about myeloma research that will be presented at the American Society of Hematology (ASH) meeting in early December, this article focuses on novel immunotherapy approaches that are being studied in clinical trials.
Abstracts for the ASH presentations are now available, although many contain preliminary information that will be updated at the meeting.
The Beacon’s ASH preview articles are intended to highlight the meeting’s most interesting myeloma-related studies.
The first several of the preview articles, which were published over …
Findings from a recent retrospective study conducted at the Mayo Clinic indicate that autologous stem cell transplantation is an effective treatment option for multiple myeloma patients with advanced kidney disease.
The majority of patients (87 percent) responded to the treatment, with 40 percent achieving a complete response. According to the researchers, this complete response rate is similar to those seen in other studies of stem cell transplantation for myeloma patients with kidney disease.
However, the researchers found little evidence that transplantation significantly improves kidney function in patients with advanced kidney …
Results from a retrospective study demonstrate that a set of protein biomarkers found in urine can be used to predict the development of acute graft-versus-host disease in patients who undergo donor stem cell transplantation.
During the study, levels of specific urine proteins were used to generate a “classification factor,” named aGvHD_MS17, designed to predict a patient’s probability of developing acute graft-versus-host disease (GVHD).
The study’s findings may allow for early detection and preemptive treatment of acute GVHD, a potentially fatal complication that can occur after transplantation using donor stem cells. …
Results from a recent study indicate that collecting more stem cells prior to a myeloma patient’s first transplant may be beneficial for future transplants.
Specifically, relapsed patients who received a second transplant with cells that had been collected prior to their first transplant, rather than those collected following the first transplant, had a lower risk of later developing myelodysplastic syndromes (MDS).
MDS is a group of blood disorders marked by ineffective production of blood cells. MDS often progresses to acute myeloid leukemia, an aggressive blood cancer in which the body …
Results from a retrospective study show that delaying stem cell transplantation following initial therapy may result in shorter progression-free survival following transplantation compared to transplantation soon after diagnosis.
However, the results also show that the timing of transplantation does not significantly impact overall survival.
The median progression-free survival after transplantation was 28 months for those who underwent early transplantation (within 12 months of diagnosis) compared to 18 months for those who underwent delayed transplantation (more than 12 months after diagnosis). This difference was not statistically significant, but the study investigators …